Clinical trial NCT00161174 - References

Non-seminomatous Testicular Cancer — Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity

Citation(s)

•   Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ
  Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995 Dec;31A(13-14):2229-38. doi: 10.1016/0959-8049(95)00460-2.
•   Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ
  Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001 Dec 18;104(25):3063-8. doi: 10.1161/hc5001.100793.
•   Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ
  Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996 Nov;14(11):2923-32. doi: 10.1200/JCO.1996.14.11.2923.
•   Boyer M, Raghavan D, Harris PJ, Lietch J, Bleasel A, Walsh JC, Anderson S, Tsang CS
  Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol. 1990 Jan;8(1):21-6. doi: 10.1200/JCO.1990.8.1.21.
•   Boyer M, Raghavan D
  Toxicity of treatment of germ cell tumors. Semin Oncol. 1992 Apr;19(2):128-42.
•   Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE
  Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993 Nov;88(5 Pt 1):2149-55. doi: 10.1161/01.cir.88.5.2149.
•   Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE
  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5. doi: 10.1016/0140-6736(92)93147-f.
•   Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH
  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986 Jul;105(1):48-51. doi: 10.7326/0003-4819-105-1-48.
•   Einhorn LH
  Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777-81. doi: 10.1200/JCO.1990.8.11.1777.
•   Evans WE, McLeod HL
  Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003 Feb 6;348(6):538-49. doi: 10.1056/NEJMra020526. No abstract available.
•   Evans WE, Relling MV
  Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 Oct 15;286(5439):487-91. doi: 10.1126/science.286.5439.487.
•   Garte S
  Metabolic susceptibility genes as cancer risk factors: time for a reassessment? Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1233-7.
•   Gerl A, Clemm C, Wilmanns W
  Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet. 1991 Aug 10;338(8763):385-6. doi: 10.1016/0140-6736(91)90521-p. No abstract available.
•   Gietema JA, de Vries EG, Sleijfer DT
  Increased incidence of cardiovascular risk factors in cured testicular cancer patients. J Clin Oncol. 1992 Oct;10(10):1652. No abstract available.
•   Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, Sleijfer DT
  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000 Mar 25;355(9209):1075-6. doi: 10.1016/s0140-6736(00)02044-4.
•   Gietema JA, Meinardi MT, van der Graaf WT, Sleijfer DT
  Syndrome X in testicular-cancer survivors. Lancet. 2001 Jan 20;357(9251):228-9. doi: 10.1016/S0140-6736(05)71326-X. No abstract available.
•   Gietema JA, Sleijfer DT, Willemse PH, Schraffordt Koops H, van Ittersum E, Verschuren WM, Kromhout D, Sluiter WJ, Mulder NH, de Vries EG
  Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med. 1992 May 1;116(9):709-15. doi: 10.7326/0003-4819-116-9-709.
•   Hansen SW, Groth S, Daugaard G, Rossing N, Rorth M
  Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol. 1988 Nov;6(11):1728-31. doi: 10.1200/JCO.1988.6.11.1728.
•   Hansen SW, Olsen N
  Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol. 1989 Jul;7(7):940-2. doi: 10.1200/JCO.1989.7.7.940.
•   Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP
  Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003 Apr 15;21(8):1513-23. doi: 10.1200/JCO.2003.04.173.
•   Innocenti F, Ratain MJ
  Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002 Mar;38(5):639-44. doi: 10.1016/s0959-8049(01)00434-8.
•   La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ
  Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998 Feb 14;351(9101):478-84. doi: 10.1016/s0140-6736(97)11144-8.
•   Lefrandt JD, Hoogenberg K, van Roon AM, Dullaart RP, Gans RO, Smit AJ
  Baroreflex sensitivity is depressed in microalbuminuric Type I diabetic patients at rest and during sympathetic manoeuvres. Diabetologia. 1999 Nov;42(11):1345-9. doi: 10.1007/s001250051448.
•   Lenz HJ
  The use and development of germline polymorphisms in clinical oncology. J Clin Oncol. 2004 Jul 1;22(13):2519-21. doi: 10.1200/JCO.2004.04.900. Epub 2004 Jun 1. No abstract available.
•   Libura J, Bettens F, Radkowski A, Tiercy JM, Piguet PF
  Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene. Eur Respir J. 2002 May;19(5):912-8. doi: 10.1183/09031936.02.00238102.
•   Makridakis NM, di Salle E, Reichardt JK
  Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics. 2000 Jul;10(5):407-13. doi: 10.1097/00008571-200007000-00004.
•   Meijer S, Sleijfer DT, Mulder NH, Sluiter WJ, Marrink J, Koops HS, Brouwers TM, Oldhoff J, van der Hem GK, Mandema E
  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer. 1983 Jun 1;51(11):2035-40. doi: 10.1002/1097-0142(19830601)51:113.0.co;2-8.
•   Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT
  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000 Apr;18(8):1725-32. doi: 10.1200/JCO.2000.18.8.1725.
•   Meinardi MT, Gietema JA, Van der Graaf WTA et al
  Long-term vascular and metabolic sequelae of chemotherapy for metastatic testicular cancer. A comparison with long-term survivors of stage I disease. PROC ASCO 2000; 19: 331a.
•   Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE
  Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat Genet. 1998 Mar;18(3):211-2. doi: 10.1038/ng0398-211. No abstract available. Erratum In: Nat Genet 1998 Aug;19(4):404.
•   Montoya SE, Ferrell RE, Lazo JS
  Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase. Cancer Res. 1997 Oct 1;57(19):4191-5.
•   Nicaud V, Raoux S, Poirier O, Cambien F, O'Reilly DS, Tiret L
  The TNF alpha/G-308A polymorphism influences insulin sensitivity in offspring of patients with coronary heart disease: the European Atherosclerosis Research Study II. Atherosclerosis. 2002 Apr;161(2):317-25. doi: 10.1016/s0021-9150(01)00648-7.
•   Nichols CR, Roth BJ, Williams SD, Gill I, Muggia FM, Stablein DM, Weiss RB, Einhorn LH
  No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol. 1992 May;10(5):760-5. doi: 10.1200/JCO.1992.10.5.760.
•   Nord C, Fossa SD, Egeland T
  Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer. 2003 Jan 13;88(1):36-41. doi: 10.1038/sj.bjc.6600714.
•   Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, et al
  Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994 Jul 2;344(8914):14-8. doi: 10.1016/s0140-6736(94)91047-2.
•   Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D
  Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol. 1992 Sep;10(9):1386-9. doi: 10.1200/JCO.1992.10.9.1386.
•   Reaven GM
  Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595-607. doi: 10.2337/diab.37.12.1595.
•   Ross R
  The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801-9. doi: 10.1038/362801a0.
•   Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH
  Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol. 1988 Aug;6(8):1239-47. doi: 10.1200/JCO.1988.6.8.1239.
•   Samuels BL, Vogelzang NJ, Kennedy BJ
  Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19(3):253-6. doi: 10.1007/BF00252982.
•   Sekine I, Saijo N
  Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol. 2001 Nov;12(11):1515-25. doi: 10.1023/a:1013164013375.
•   Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH, Schraffordt Koops H, van Oosterom AT, ten Bokkel Huinink WW, Pinedo HM
  Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989 Aug;7(8):1099-104. doi: 10.1200/JCO.1989.7.8.1099.
•   Talvensaari KK, Lanning M, Tapanainen P, Knip M
  Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5. doi: 10.1210/jcem.81.8.8768873.
•   Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M
  Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet. 2000 Sep 16;356(9234):993-7. doi: 10.1016/S0140-6736(00)02717-3.
•   Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD Jr
  Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39. doi: 10.1093/jnci/89.19.1429.
•   Tuimala J, Szekely G, Gundy S, Hirvonen A, Norppa H
  Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis. 2002 Jun;23(6):1003-8. doi: 10.1093/carcin/23.6.1003.
•   Vaughn DJ, Meadows AT
  Cancer survivorship research: the best is yet to come. J Clin Oncol. 2002 Feb 15;20(4):888-90. doi: 10.1200/JCO.2002.20.4.888. No abstract available.
•   Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ
  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981 Sep;95(3):288-92. doi: 10.7326/0003-4819-95-3-288.
•   Vogelzang NJ, Frenning DH, Kennedy BJ
  Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1159-60. No abstract available.
•   Vogelzang NJ, Torkelson JL, Kennedy BJ
  Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985 Dec 15;56(12):2765-70. doi: 10.1002/1097-0142(19851215)56:123.0.co;2-2.
•   Weinshilboum R
  Inheritance and drug response. N Engl J Med. 2003 Feb 6;348(6):529-37. doi: 10.1056/NEJMra020021. No abstract available.
•   Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M
  Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002 Dec 12;347(24):1916-23. doi: 10.1056/NEJMoa021445.
•   Yudkin JS, Forrest RD, Jackson CA
  Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988 Sep 3;2(8610):530-3. doi: 10.1016/s0140-6736(88)92657-8.

Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity. (KWF RUG 2004-3157)

Details for clinical trial NCT00161174